Epstein-Barr Virus in Human Malignancy: A Special Reference to Epstein-Barr Virus associated Gastric Carcinoma.
- Author:
Mee Soo CHANG
1
;
Woo Ho KIM
Author Information
1. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. woohokim@snu.ac.kr
- Publication Type:Review
- Keywords:
Human herpes virus 4;
Epstein-Barr virus (EBV);
Oncogenic virus;
Stomach neoplasms;
Lymphoma;
EBV-targeted treatment
- MeSH:
Adult;
B-Lymphocytes;
Biology;
Epstein-Barr Virus Infections;
Herpesvirus 4, Human*;
Humans*;
Infectious Mononucleosis;
International Agencies;
Lymphoma;
Oncogenic Viruses;
Stomach Neoplasms;
Vaccination
- From:Cancer Research and Treatment
2005;37(5):257-267
- CountryRepublic of Korea
- Language:English
-
Abstract:
Epstein-Bar virus (EBV), a human herpesvirus, establishes a life-long persistent infection in 90~95% of human adult population worldwide. EBV is the etiologic agent of infectious mononucleosis, and EBV is associated with a variety of human malignancy including lymphoma and gastric carcinoma. Recently, EBV has been classified as group 1 carcinogen by the WHO International Agency for Research on Cancer. Evidence is presented which suggests that failures of the EBV-specific immunity may play a role in the pathogenesis of EBV-associated malignancy. At present, the precise mechanisms by which EBV transforms B lymphocytes have been disclosed. Encouragingly, they have had enough success so far to keep them enthusiastic about novel therapeutic trial in the field of EBV-associated lymphoma. However, information on EBV-associated gastric carcinoma is still at dawn. This article reviews EBV biology, immunological response of EBV infection, unique oncogenic property of EBV, peculiarity of EBV-associated gastric carcinoma, and lastly, EBV-targeted therapy and vaccination.
